<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2016.5007</article-id>
<article-id pub-id-type="publisher-id">mmr-13-05-3779</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Screening for genes and subnetworks associated with pancreatic cancer based on the gene expression profile</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>LONG</surname><given-names>JIN</given-names></name><xref ref-type="corresp" rid="c1-mmr-13-05-3779"/></contrib>
<contrib contrib-type="author">
<name><surname>LIU</surname><given-names>ZHE</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>WU</surname><given-names>XINGDA</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>XU</surname><given-names>YUANHONG</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>GE</surname><given-names>CHUNLIN</given-names></name></contrib>
<aff id="af1-mmr-13-05-3779">Department of General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China</aff></contrib-group>
<author-notes>
<corresp id="c1-mmr-13-05-3779">Correspondence to: Dr Jin Long, Department of General Surgery, The First Hospital of China Medical University, 155 Nanjing Bei Street, Shenyang, Liaoning 110001, P.R. China, E-mail: <email>jinlongjlq@163.com</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>05</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>03</month>
<year>2016</year></pub-date>
<volume>13</volume>
<issue>5</issue>
<fpage>3779</fpage>
<lpage>3786</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>04</month>
<year>2015</year></date>
<date date-type="accepted">
<day>17</day>
<month>02</month>
<year>2016</year></date></history>
<permissions>
<copyright-statement>Copyright: &#x000A9; Long et al.</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions>
<abstract>
<p>The present study aimed to screen for potential genes and subnetworks associated with pancreatic cancer (PC) using the gene expression profile. The expression profile GSE 16515 was downloaded from the Gene Expression Omnibus database, which included 36 PC tissue samples and 16 normal samples. Limma package in R language was used to screen differentially expressed genes (DEGs), which were grouped as up- and downregulated genes. Then, PFSNet was applied to perform subnetwork analysis for all the DEGs. Moreover, Gene Ontology (GO) and REACTOME pathway enrichment analysis of up- and downregulated genes was performed, followed by protein-protein interaction (PPI) network construction using Search Tool for the Retrieval of Interacting Genes Search Tool for the Retrieval of Interacting Genes. In total, 1,989 DEGs including 1,461 up- and 528 downregulated genes were screened out. Subnetworks including pancreatic cancer in PC tissue samples and intercellular adhesion in normal samples were identified, respectively. A total of 8 significant REACTOME pathways for upregulated DEGs, such as hemostasis and cell cycle, mitotic were identified. Moreover, 4 significant REACTOME pathways for downregulated DEGs, including regulation of &#x003B2;-cell development and transmembrane transport of small molecules were screened out. Additionally, DEGs with high connectivity degrees, such as <italic>CCNA2</italic> (cyclin A2) and <italic>PBK</italic> (PDZ binding kinase), of the module in the protein-protein interaction network were mainly enriched with cell-division cycle. <italic>CCNA2</italic> and <italic>PBK</italic> of the module and their relative pathway cell-division cycle, and two subnetworks (pancreatic cancer and intercellular adhesion subnetworks) may be pivotal for further understanding of the molecular mechanism of PC.</p></abstract>
<kwd-group>
<kwd>pancreatic cancer</kwd>
<kwd>differentially expressed genes</kwd>
<kwd>function enrichment</kwd>
<kwd>protein-protein interaction network</kwd>
<kwd>molecular mechanism</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Pancreatic cancer (PC), a digestive system tumor, is one of the most aggressive types of cancer. With a high degree of malignancy, rapid progression and poor prognosis, the 1- and 5-year survival rates of patients with PC are only 8 and 3%, respectively (<xref rid="b1-mmr-13-05-3779" ref-type="bibr">1</xref>). American Cancer Society statistics reported that there were an estimated 36,800 related fatalities and 43,140 new cases of PC in 2010. PC remains the fourth leading cause of cancer-related mortality in the United States, despite advances in detection, chemotherapy and surgery (<xref rid="b2-mmr-13-05-3779" ref-type="bibr">2</xref>). In developing countries, for example, in China, the incidence of PC has also been markedly increasing during the past several decades, and PC has been ranked the sixth leading cause of death from malignant disease (<xref rid="b3-mmr-13-05-3779" ref-type="bibr">3</xref>).</p>
<p>The inability to detect PC in its early treatable stage may be the critical factor contributing to high mortality. PC is characterized by the lack of notable clinical symptoms and patients often present with symptoms, such as back pain, weight loss, and digestive problems (<xref rid="b4-mmr-13-05-3779" ref-type="bibr">4</xref>). As many as 80% of newly diagnosed patients with PC are already in the metastatic stage of the disease, which limits the potential for therapeutic intervention (<xref rid="b5-mmr-13-05-3779" ref-type="bibr">5</xref>). At this stage, several epigenetic as well as genetic changes have taken place and result in the silencing of tumor suppressors and overexpression of oncogenes, ultimately leading to tumor progression (<xref rid="b6-mmr-13-05-3779" ref-type="bibr">6</xref>). In recent years, important advances have been made to understand the molecular biology of PC and genetic analyses have verified that the basis of this malignant disease is heterogenous and complex (<xref rid="b7-mmr-13-05-3779" ref-type="bibr">7</xref>). The occurrence and pathogenesis of PC, however, is not yet completely understood.</p>
<p>Similar to the majority of tumors, the development and growth of PC is a multistep process including initiation, progression, invasion and ultimately metastasis. Each step in this process is considered to be driven by the accumulation of genetic alterations (<xref rid="b8-mmr-13-05-3779" ref-type="bibr">8</xref>). Numerous studies involving PC have been conducted in order to identify cancer-causing genes over the past decade, and as a result several cancer-related genes have been identified (<xref rid="b9-mmr-13-05-3779" ref-type="bibr">9</xref>,<xref rid="b10-mmr-13-05-3779" ref-type="bibr">10</xref>). For instance, <italic>DPC4</italic>, which encodes SMAD family member 4 (SMAD4), is found to be inactivated in ~50% of all PCs (<xref rid="b11-mmr-13-05-3779" ref-type="bibr">11</xref>). <italic>KRAS</italic>, an oncogene which is associated with cell survival, proliferation and differentiation, has been identified in &gt;90% of patients with PC, with the majority of these being point mutations at codon 12. In addition, it has been demonstrated that the detection of the <italic>KRAS</italic> mutation may be useful in identifying patients at high risk for developing PC (<xref rid="b12-mmr-13-05-3779" ref-type="bibr">12</xref>). The identification and characterization of cancer-associated genes have increased the understanding of PC development. However, the survival rate has not improved as much in the past years due to the lack of early diagnosis and effective chemotherapeutic treatments. Therefore, identification of genes associated with the development of PC is required.</p>
<p>To test the hypothesis that the FK506-binding protein 51 (<italic>FKBP51</italic>) may function as a tumor suppressor, Pei <italic>et al</italic> (<xref rid="b13-mmr-13-05-3779" ref-type="bibr">13</xref>) performed microarray analysis and submitted the expression profile, including 36 pancreatic cancer tissue samples and 16 normal samples, to the Gene Expression Omnibus database (GEO). This previous study was predominantly focused on the functional mechanism of the single gene <italic>FKBP51</italic>. Based on the gene expression profile submitted by Pei <italic>et al</italic> (<xref rid="b13-mmr-13-05-3779" ref-type="bibr">13</xref>) and bioinformatics methods, differentially expressed genes (DEGs) between PC tissue samples and normal samples were determined in the present study. Furthermore, functional annotation of DEGs was conducted, followed by the construction of the protein-protein interaction (PPI) network. This study aimed to increase the understanding of the mechanism underlying PC development.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Affymetrix microarray data</title>
<p>The expression profiles were accessible at the National Center of Biotechnology Information (NCBI) Gene Expression Omnibus database (<ext-link xlink:href="http://www.ncbi.nlm.nih.gov/geo" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/geo</ext-link>) using the series accession number GSE16515, which was deposited by Pei <italic>et al</italic> (<xref rid="b13-mmr-13-05-3779" ref-type="bibr">13</xref>). This data set was based on the GPL570 platform of &#x0005B;Affymetrix Human Genome U133 Plus 2.0 Array (HG-U133_Plus_2); Affymetrix, Santa Clara, CA, USA&#x0005D; and updated on Aug 22, 2014. A total of 52 chips were divided into 2 groups: PC tissue samples (T-group, n=36) and normal samples (N-group, n=16).</p></sec>
<sec>
<title>Data processing and DEG identification</title>
<p>The probe-level data were firstly transformed into gene expression data. Then background corrections and quartile data normalization were conducted using the robust multiarray average (RMA) in the affy package (Fred Hutchinson Cancer Research Center, Seattle, WA, USA) with default parameters (<xref rid="b14-mmr-13-05-3779" ref-type="bibr">14</xref>).</p>
<p>To screen DEGs between the T-group and N-group, the Limma package (Linear Models for Microarray Data) in R language was used (<xref rid="b15-mmr-13-05-3779" ref-type="bibr">15</xref>). The raw P-value was adjusted to the false discovery rate based on the Benjamini-Hochberg approach (<xref rid="b16-mmr-13-05-3779" ref-type="bibr">16</xref>,<xref rid="b17-mmr-13-05-3779" ref-type="bibr">17</xref>) using the Limma package (version 3.22.1; Fred Hutchinson Cancer Research Center). DEGs were identified with the cutoff value of FDR&lt;0.05 and |log (fold change)|&gt;1 (<xref rid="b18-mmr-13-05-3779" ref-type="bibr">18</xref>,<xref rid="b19-mmr-13-05-3779" ref-type="bibr">19</xref>).</p></sec>
<sec>
<title>Subnetwork analysis</title>
<p>Paired Fuzzy SNet (PFSNet) (<xref rid="b20-mmr-13-05-3779" ref-type="bibr">20</xref>) is a powerful method to identify smaller parts of pathways termed subnetworks. Comparison with previously published methods shows that significant subnetworks (and the genes therein) identified by PFSNet are up to 51% (64%) more consistent across independent datasets of the same disease phenotypes, even for datasets based on different platforms (<xref rid="b20-mmr-13-05-3779" ref-type="bibr">20</xref>). In order to obtain the genes and subnetworks that may be associated with the biological characteristics of a sample, PFSNet was used in this study to analyze the subnetworks of the genes from the T-group as well as the N-group based on pathways from PathwayAPI (<xref rid="b21-mmr-13-05-3779" ref-type="bibr">21</xref>), which integrated Wikipathways (<xref rid="b22-mmr-13-05-3779" ref-type="bibr">22</xref>), Kyoto Encyclopedia of Genes and Genomes (KEGG) (<xref rid="b23-mmr-13-05-3779" ref-type="bibr">23</xref>) and Ingenuity (<xref rid="b24-mmr-13-05-3779" ref-type="bibr">24</xref>). Steps were conducted as follows: i) The pathways were divided into several subnetworks according to the genes with high expression level; ii) the subnetwork of each group was scored as 1 or 2, based on the equation as previously described (<xref rid="b20-mmr-13-05-3779" ref-type="bibr">20</xref>); iii) the difference of scores in each group was evaluated by t-test and the subnetworks with significantly different scores were screened out. Parameters in the PFSNet were set as <italic>b</italic>= 0.5, <italic>t</italic><sub>1</sub>=0.95, and <italic>t</italic><sub>2</sub>= 0.8.</p></sec>
<sec>
<title>Gene ontology (GO) function annotation and pathway enrichment analysis</title>
<p>The Database for Annotation Visualization and Integrated Discovery (DAVID) provides a comprehensive set of functional annotation tools to determined the biological meaning of a large list of genes (<xref rid="b25-mmr-13-05-3779" ref-type="bibr">25</xref>). DAVID was used for GO function annotation and REACTOME pathway enrichment analysis of the up- and downregulated genes, respectively. P&lt;0.05 was selected as the cut-off criterion.</p></sec>
<sec>
<title>PPI network construction</title>
<p>Search Tool for the Retrieval of Interacting Genes (STRING, <ext-link xlink:href="http://string-db.org/" ext-link-type="uri">http://string-db.org/</ext-link>) is an online database which includes experimental as well as predicted interaction information and comprises &gt;1,100 completely sequenced organisms (<xref rid="b26-mmr-13-05-3779" ref-type="bibr">26</xref>). The protein interactions in the STRING database were shown with a confidence score. To identify the interactive associations between the target genes and other genes, the up- and downregulated genes between the T-group and N-group were inputted into STRING and protein pairs with a confidence score &#x02265;0.7 were considered to be significant. Cytoscape (National Institute of General Medical Sciences of the National Institutes of Health, Bethesda, MD, USA) was performed to visualize the PPI network.</p>
<p>The PPI network was complicated; thus, further analysis was required to expose the enriched functional modules of the PPI network using ClusterONE (Clustering with overlapping neighborhood expansion) in Cytoscape (<xref rid="b27-mmr-13-05-3779" ref-type="bibr">27</xref>). Then DAVID was used to annotate the function of genes in each module.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>DEG identification</title>
<p>After data preprocessing, the normalized expression profile data were analyzed using Limma package in R language. With FDR&lt;0.05 and |log (fold change)|&gt;1, 1,989 DEGs including 1,461 up- and 528 downregulated genes, were screened out in the T-group compared with the N-group.</p></sec>
<sec>
<title>Subnetwork analysis</title>
<p>In the N-group, 5 significant subnetworks were identified and were shown to be associated with glutathione metabolism (<xref rid="f1-mmr-13-05-3779" ref-type="fig">Fig. 1A</xref>), leucine and isoleucine metabolism (<xref rid="f1-mmr-13-05-3779" ref-type="fig">Fig. 1B</xref>), pancreatic cancer (<xref rid="f1-mmr-13-05-3779" ref-type="fig">Fig. 1C</xref>), calcium signaling pathway (<xref rid="f1-mmr-13-05-3779" ref-type="fig">Fig. 1D</xref>) and the mitogen-activated protein kinase pathway (<xref rid="f1-mmr-13-05-3779" ref-type="fig">Fig. 1E</xref>), respectively. Significant subnetworks of genes from the T-group were in association with galactose metabolism (<xref rid="f2-mmr-13-05-3779" ref-type="fig">Fig. 2A</xref>), alanine, aspartic acid and glutamic acid metabolism (<xref rid="f2-mmr-13-05-3779" ref-type="fig">Fig. 2B</xref>), intercellular cell adhesion (<xref rid="f2-mmr-13-05-3779" ref-type="fig">Fig. 2C</xref>) and contraction of vascular smooth muscle (<xref rid="f2-mmr-13-05-3779" ref-type="fig">Fig. 2D and E</xref>).</p></sec>
<sec>
<title>Function and pathway annotation</title>
<p>To gain further insight into the function of the identified DEGs, the online biological classification software DAVID was applied to annotate the DEGs. The upregulated genes were enriched in 14 GO subcategories with the most genes enriched in the cell adhesion pathway (<xref rid="tI-mmr-13-05-3779" ref-type="table">Table I</xref>). The downregulated genes were enriched in 9 subcategories with the highest number of genes enriched in the proteolysis pathway (<xref rid="tI-mmr-13-05-3779" ref-type="table">Table I</xref>). In addition, 8 significant REACTOME pathways for upregulated genes, such as metabolism of carbohydrates, hemostasis and cell cycle, mitotic were identified (<xref rid="f3-mmr-13-05-3779" ref-type="fig">Fig. 3A</xref>). Moreover, 4 significant REACTOME pathways for downregulated genes, regulation of &#x003B2;-cell development, transmembrane transport of small molecules, hemostasis and metabolism of amino acids were screened out (<xref rid="f3-mmr-13-05-3779" ref-type="fig">Fig. 3B</xref>).</p></sec>
<sec>
<title>PPI construction and module analysis</title>
<p>The up- and downregulated genes between the T-group and N-group were input into the STRING database to identify the significant interactions with a confidence score of &#x02265;0.7. The PPI network reveals the molecular mechanisms of pancreatic cancer, but it contains too many nodes and interactions to select the useful information. Therefore, the functional modules in the PPI network were mined by ClusterONE. In the current study, the significant module with the lowest P-value for the upregulated DEGs was displayed in <xref rid="f4-mmr-13-05-3779" ref-type="fig">Fig. 4A</xref>, and 5 DEGs with higher connectivity degrees including cyclin-dependent kinase 1 (<italic>CDK1</italic>), maternal embryonic leucine zipper kinase (<italic>MELK</italic>), PDZ-binding kinase (<italic>PBK</italic>), Cyclin A2 (<italic>CCNA2</italic>) and nucleolar and spindle associated protein 1 (<italic>NUSAP1</italic>) were included in this module. GO analysis showed that the DEGs in this module were predominantly associated with cell-division cycle (<xref rid="tII-mmr-13-05-3779" ref-type="table">Table II</xref>). While, 5 hub genes with the higher degrees including albumin (<italic>ALB</italic>), carboxypeptidase A1 (pancreatic) (<italic>CPA1</italic>), colipase, pancreatic (<italic>CLPS</italic>), epidermal growth factor (<italic>EGF</italic>) and complement component 5 (<italic>C5</italic>) were identified in the significant module with the lowest P-value for the downregulated DEGs with the lowest P-values, which is shown in <xref rid="f4-mmr-13-05-3779" ref-type="fig">Fig. 4B</xref>. Moreover, the DEGs in this module predominantly participated in biological processes, such as response to wounding, endogenous stimulus and regulation of cell proliferation (<xref rid="tII-mmr-13-05-3779" ref-type="table">Table II</xref>).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>PC is one of the leading causes of cancer-related mortality worldwide; however, the molecular mechanisms of PC progression remain unclear. With the rapid expansion of knowledge on genomics, emerging evidence suggests that the initiation, progression, invasion and metastasis of PC are generally caused by the differential expression of genes. In the present study, a total of 1,989 DEGs including 1,461 up- and 528 downregulated genes were screened out. In line with the results of the study by Pei <italic>et al</italic> (<xref rid="b13-mmr-13-05-3779" ref-type="bibr">13</xref>), <italic>FKBP5</italic> was identified as one of the downregulated genes in the PC samples. To understand the interaction of these DEGs, a PPI network was constructed and the significant module with the lowest P-value for upregulated genes with the top 5 nodes of <italic>CDK1</italic>, <italic>MELK</italic>, <italic>PBK</italic>, <italic>CCNA2</italic> and <italic>NUSAP1</italic> and the module with the lowest P-value for downregulated genes with the top 5 nodes of <italic>ALB</italic>, <italic>CPA1</italic>, <italic>CLPS</italic>, <italic>EGF</italic> and <italic>C5</italic> were identified. Among all these proteins, <italic>CDK1</italic>, <italic>ALB</italic>, <italic>CPA1</italic>, <italic>CLPS</italic> and <italic>EGF</italic> were verified to be associated with PC (<xref rid="b28-mmr-13-05-3779" ref-type="bibr">28</xref>&#x02013;<xref rid="b31-mmr-13-05-3779" ref-type="bibr">31</xref>). Moreover, the association of <italic>MELK</italic> and <italic>C5</italic> with PC have been demonstrated in certain studies (<xref rid="b32-mmr-13-05-3779" ref-type="bibr">32</xref>&#x02013;<xref rid="b34-mmr-13-05-3779" ref-type="bibr">34</xref>). However, according to the present results, <italic>CCNA2</italic> and <italic>PBK</italic>, which have not previously been directly associated with PC, may be pivotal for the initiation and progression of PC. In addition, certain subnetworks may be important in PC via the differential expression of genes involved, such as the subnetwork directly associated with PC and the subnetwork associated with intercellular cell adhesion.</p>
<p>Cyclins are a family of proteins that control the progression of cells through the cell cycle by activating cyclin-dependent kinases (CDK) (<xref rid="b35-mmr-13-05-3779" ref-type="bibr">35</xref>). As a member of the cyclin family, CCNA2 is produced at the onset of DNA synthesis in proliferating somatic cells and is critical in cell cycle progression by regulation of transition from G1 to S phase (<xref rid="b36-mmr-13-05-3779" ref-type="bibr">36</xref>). Genetic variants of <italic>CCNA2</italic>, which may affect the function of the encoded protein by changing gene expression or by altering the protein structure, are found to significantly increase the risk of cancer development in a tissue-specific manner, such as colon, liver and lung cancer (<xref rid="b37-mmr-13-05-3779" ref-type="bibr">37</xref>). In addition, Gao <italic>et al</italic> (<xref rid="b38-mmr-13-05-3779" ref-type="bibr">38</xref>) reported that <italic>CCNA2</italic> was a biomarker for the prognosis of breast cancer and a promising target for developing novel strategies to prevent or even reverse tamoxifen resistance. In addition, the expression of <italic>CCNA2</italic> may aid in monitoring tamoxifen efficacy and directing personalized therapies in patients with breast cancer (<xref rid="b38-mmr-13-05-3779" ref-type="bibr">38</xref>). Few previous studies have focused on the association of <italic>CCNA2</italic> and PC, while high throughput bioinformatics analysis in the present study indicates that <italic>CCNA2</italic> may be important for the initiation and development of PC. In the present study, <italic>CCNA2</italic> was found to be upregulated in PC tissue samples, and functional analysis demonstrates that <italic>CCNA2</italic> was predominantly enriched in the cell cycle pathway and participates in biological processes, such as regulation of cell proliferation, regulation of cell cycle, cell cycle checkpoint and mitosis. These findings were concordant with those of previous studies (<xref rid="b39-mmr-13-05-3779" ref-type="bibr">39</xref>,<xref rid="b40-mmr-13-05-3779" ref-type="bibr">40</xref>). Therefore, it was hypothesized that <italic>CCNA2</italic> may be important in the pathogenesis of PC via regulation of the cell cycle and mitosis, which may further influence tumor occurrence.</p>
<p>PBK, also known as PDZ-binding kinase, is a mitotic protein kinase and its encoding gene, <italic>PBK</italic> was found to be upregulated in PC tissue samples. Studying upregulated kinases in cancer may provide important clues as to the mechanism of malignant conversion (<xref rid="b41-mmr-13-05-3779" ref-type="bibr">41</xref>,<xref rid="b42-mmr-13-05-3779" ref-type="bibr">42</xref>). PBK is phosphorylated <italic>in vitro</italic> by Cdc2-cyclin B at a site in the amino terminus (Thr 9) which is implicated in the binding of &#x003B1;-tubulin, and then localizes to mitotic spindles and spindle poles during metaphase (<xref rid="b43-mmr-13-05-3779" ref-type="bibr">43</xref>). Studies regarding <italic>PBK</italic> have demonstrated that the expression of <italic>PBK</italic> is regulated by cell cycle-specific transcription factors, such as E2F and CREB/ATF, and knockdown expression of <italic>PBK</italic> may lead to cytokinetic dysfunction in breast cancer (<xref rid="b44-mmr-13-05-3779" ref-type="bibr">44</xref>,<xref rid="b45-mmr-13-05-3779" ref-type="bibr">45</xref>). Ayll&#x000F3;n <italic>et al</italic> (<xref rid="b46-mmr-13-05-3779" ref-type="bibr">46</xref>) suggested that <italic>PBK</italic> is involved in DNA damage sensing and repair via phosphorylating c-H2AX. Nandi <italic>et al</italic> (<xref rid="b47-mmr-13-05-3779" ref-type="bibr">47</xref>) confirmed that with western immunoblotting and immunoprecipation, and yeast two-hybrid analysis, PBK can directly interact with p53, downregulate its expression and attenuate G2/M checkpoint in fibrosarcoma cells, which was hypothesized to be a plausible explanation for the role of <italic>PBK</italic> in augmenting tumor cell growth. Similarly, the GO-biological process enrichment in the present study predicted that <italic>PBK</italic> was predominantly associated with nuclear division, cell division, M phase of mitotic cell cycle, and <italic>PBK</italic> with higher connectivity degree in the module with the lowest P-value of upregulated genes was enriched in cell division cycle. Based on these results, it was inferred that <italic>PBK</italic> may influence the occurrence of PC by regulating the mitotic cell cycle and other biological processes.</p>
<p>Intercellular cell adhesion determines the polarity of cells and participates in the maintenance of tissues (<xref rid="b48-mmr-13-05-3779" ref-type="bibr">48</xref>). Several studies have shown that cell-cell adhesiveness is generally reduced in human cancer, which may result in influences as follows: Reduced intercellular adhesiveness allows loss and disruption of cell-cell adhesion, resulting in destruction of histological structure, which is the morphological hallmark of malignant tumors (<xref rid="b48-mmr-13-05-3779" ref-type="bibr">48</xref>). Conversely, reduced intercellular adhesiveness is also indispensable for cancer invasion and metastasis (<xref rid="b49-mmr-13-05-3779" ref-type="bibr">49</xref>). In line with the previous studies, subnetworks associated with intercellular cell adhesion were found to be significant in the T-group, and the majority of the genes in this subnetwork were identified to be upregulated in PC. Accordingly, intercellular cell adhesion may be important in the progression of PC.</p>
<p>The significant subnetwork directly associated with PC consisted of six genes, <italic>VEGFA, NFKB1, STAT3, PGF, RAC1</italic> and <italic>ARHGEF6.</italic> Expression levels of the majority of these genes were identified to be significantly higher in PC samples and this subnetwork is directly involved in PC via the differential expression of genes involved. For instance, <italic>STAT3</italic> is confirmed to be vital in anti-pancreatic cancer effects through its contributions to the positive feedback loop between reactive oxygen species and autophagy (<xref rid="b50-mmr-13-05-3779" ref-type="bibr">50</xref>). The concentration of <italic>PGF</italic> is found to be significantly increased in pancreatic carcinoma compared with tumor-free tissue (<xref rid="b51-mmr-13-05-3779" ref-type="bibr">51</xref>). Moreover, activation of <italic>RAC1</italic>-dependent superoxide generation leads to PC cell proliferation and inhibition of <italic>RAC1</italic> may be a potential therapeutic strategy (<xref rid="b52-mmr-13-05-3779" ref-type="bibr">52</xref>). Hence, as demonstrated, subnetworks directly associated with pancreatic cancer may be crucial in the pathogenesis of PC.</p>
<p>In conclusion, the results of this study may increase the understanding of the mechanism of the occurrence and development of PC. <italic>CCNA2</italic> and <italic>PBK</italic> of the module and their relative pathway cell-division cycle may be pivotal for understanding the molecular mechanism of PC. In addition, two subnetworks (pancreatic cancer subnetwork and intercellular adhesion subnetwork) may be highly associated with PC. However, the whole study was conducted based on bioinformatics methods, and the conclusions have not been verified by corresponding experiments yet. Thus, further experiments are urgently required to confirm the results of this study.</p></sec></body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-mmr-13-05-3779"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Hamm</surname><given-names>J</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Hecht</surname><given-names>JR</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Au</surname><given-names>HJ</given-names></name><name><surname>Murawa</surname><given-names>P</given-names></name><name><surname>Walde</surname><given-names>D</given-names></name><name><surname>Wolff</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the national cancer institute of canada clinical trials group</article-title><source>J Clin Oncol</source><volume>25</volume><fpage>1960</fpage><lpage>1966</lpage><year>2007</year><pub-id pub-id-type="doi">10.1200/JCO.2006.07.9525</pub-id><pub-id pub-id-type="pmid">17452677</pub-id></element-citation></ref>
<ref id="b2-mmr-13-05-3779"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name></person-group><article-title>Cancer statistics, 2010</article-title><source>CA Cancer J Clin</source><volume>60</volume><fpage>277</fpage><lpage>300</lpage><year>2010</year><pub-id pub-id-type="doi">10.3322/caac.20073</pub-id><pub-id pub-id-type="pmid">20610543</pub-id></element-citation></ref>
<ref id="b3-mmr-13-05-3779"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>GP</given-names></name><name><surname>Xiao</surname><given-names>ZW</given-names></name><name><surname>Liu</surname><given-names>ZQ</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China</article-title><source>Cancer Lett</source><volume>346</volume><fpage>273</fpage><lpage>277</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.canlet.2014.01.004</pub-id><pub-id pub-id-type="pmid">24462819</pub-id></element-citation></ref>
<ref id="b4-mmr-13-05-3779"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Diamandis</surname><given-names>EP</given-names></name><name><surname>Blasutig</surname><given-names>IM</given-names></name></person-group><article-title>Strategies for discovering novel pancreatic cancer biomarkers</article-title><source>J Proteomics</source><volume>81</volume><fpage>126</fpage><lpage>134</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.jprot.2012.09.025</pub-id><pub-id pub-id-type="pmcid">3561491</pub-id></element-citation></ref>
<ref id="b5-mmr-13-05-3779"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pliarchopoulou</surname><given-names>K</given-names></name><name><surname>Pectasides</surname><given-names>D</given-names></name></person-group><article-title>Pancreatic cancer: Current and future treatment strategies</article-title><source>Cancer Treat Rev</source><volume>35</volume><fpage>431</fpage><lpage>436</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.ctrv.2009.02.005</pub-id><pub-id pub-id-type="pmid">19328630</pub-id></element-citation></ref>
<ref id="b6-mmr-13-05-3779"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Goggins</surname><given-names>M</given-names></name></person-group><article-title>The role of epigenetic alterations in pancreatic cancer</article-title><source>J Hepatobiliary Pancreat Surg</source><volume>13</volume><fpage>286</fpage><lpage>295</lpage><year>2006</year><pub-id pub-id-type="doi">10.1007/s00534-005-1057-1</pub-id><pub-id pub-id-type="pmid">16858539</pub-id></element-citation></ref>
<ref id="b7-mmr-13-05-3779"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Angenendt</surname><given-names>P</given-names></name><name><surname>Mankoo</surname><given-names>P</given-names></name><name><surname>Carter</surname><given-names>H</given-names></name><name><surname>Kamiyama</surname><given-names>H</given-names></name><name><surname>Jimeno</surname><given-names>A</given-names></name><etal/></person-group><article-title>Core signaling pathways in human pancreatic cancers revealed by global genomic analyses</article-title><source>Science</source><volume>321</volume><fpage>1801</fpage><lpage>1806</lpage><year>2008</year><pub-id pub-id-type="doi">10.1126/science.1164368</pub-id><pub-id pub-id-type="pmid">18772397</pub-id><pub-id pub-id-type="pmcid">2848990</pub-id></element-citation></ref>
<ref id="b8-mmr-13-05-3779"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logsdon</surname><given-names>CD</given-names></name><name><surname>Simeone</surname><given-names>DM</given-names></name><name><surname>Binkley</surname><given-names>C</given-names></name><name><surname>Arumugam</surname><given-names>T</given-names></name><name><surname>Greenson</surname><given-names>JK</given-names></name><name><surname>Giordano</surname><given-names>TJ</given-names></name><name><surname>Misek</surname><given-names>DE</given-names></name><name><surname>Kuick</surname><given-names>R</given-names></name><name><surname>Hanash</surname><given-names>S</given-names></name></person-group><article-title>Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer</article-title><source>Cancer Res</source><volume>63</volume><fpage>2649</fpage><lpage>2657</lpage><year>2003</year><pub-id pub-id-type="pmid">12750293</pub-id></element-citation></ref>
<ref id="b9-mmr-13-05-3779"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Analysis of dysregulation of immune system in pancreatic cancer based on gene expression profile</article-title><source>Mol Biol Rep</source><volume>41</volume><fpage>4361</fpage><lpage>4367</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s11033-014-3307-2</pub-id><pub-id pub-id-type="pmid">24619357</pub-id></element-citation></ref>
<ref id="b10-mmr-13-05-3779"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><article-title>Molecular genetic alterations in ductal pancreatic adenocarcinomas</article-title><source>Med Clin North Am</source><volume>84</volume><fpage>691</fpage><lpage>695</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0025-7125(05)70251-0</pub-id><pub-id pub-id-type="pmid">10872425</pub-id></element-citation></ref>
<ref id="b11-mmr-13-05-3779"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Hong</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Song</surname><given-names>KB</given-names></name><name><surname>Park</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name></person-group><article-title>Genetic alterations of K-ras, p53, c-erbB-2 and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival</article-title><source>Pancreas</source><volume>42</volume><fpage>216</fpage><lpage>222</lpage><year>2013</year><pub-id pub-id-type="doi">10.1097/MPA.0b013e31825b6ab0</pub-id><pub-id pub-id-type="pmid">23344532</pub-id></element-citation></ref>
<ref id="b12-mmr-13-05-3779"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fryzek</surname><given-names>JP</given-names></name><name><surname>Garabrant</surname><given-names>DH</given-names></name><name><surname>Schenk</surname><given-names>M</given-names></name><name><surname>Kinnard</surname><given-names>M</given-names></name><name><surname>Greenson</surname><given-names>JK</given-names></name><name><surname>Sarkar</surname><given-names>FH</given-names></name></person-group><article-title>The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations</article-title><source>Int J Gastrointest Cancer</source><volume>37</volume><fpage>139</fpage><lpage>145</lpage><year>2006</year></element-citation></ref>
<ref id="b13-mmr-13-05-3779"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Fridley</surname><given-names>BL</given-names></name><name><surname>Jenkins</surname><given-names>GD</given-names></name><name><surname>Kalari</surname><given-names>KR</given-names></name><name><surname>Lingle</surname><given-names>W</given-names></name><name><surname>Petersen</surname><given-names>G</given-names></name><name><surname>Lou</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt</article-title><source>Cancer Cell</source><volume>16</volume><fpage>259</fpage><lpage>266</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.ccr.2009.07.016</pub-id><pub-id pub-id-type="pmid">19732725</pub-id><pub-id pub-id-type="pmcid">2755578</pub-id></element-citation></ref>
<ref id="b14-mmr-13-05-3779"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorsey</surname><given-names>ER</given-names></name><name><surname>Constantinescu</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>JP</given-names></name><name><surname>Biglan</surname><given-names>KM</given-names></name><name><surname>Holloway</surname><given-names>RG</given-names></name><name><surname>Kieburtz</surname><given-names>K</given-names></name><name><surname>Marshall</surname><given-names>FJ</given-names></name><name><surname>Ravina</surname><given-names>BM</given-names></name><name><surname>Schifitto</surname><given-names>G</given-names></name><name><surname>Siderowf</surname><given-names>A</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name></person-group><article-title>Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030</article-title><source>Neurology</source><volume>68</volume><fpage>384</fpage><lpage>386</lpage><year>2007</year><pub-id pub-id-type="doi">10.1212/01.wnl.0000247740.47667.03</pub-id></element-citation></ref>
<ref id="b15-mmr-13-05-3779"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delhomme</surname><given-names>N</given-names></name><name><surname>Padioleau</surname><given-names>I</given-names></name><name><surname>Furlong</surname><given-names>EE</given-names></name><name><surname>Steinmetz</surname><given-names>LM</given-names></name></person-group><article-title>easyRNASeq: A bioconductor package for processing RNA-Seq data</article-title><source>Bioinformatics</source><volume>28</volume><fpage>2532</fpage><lpage>2533</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/bioinformatics/bts477</pub-id><pub-id pub-id-type="pmid">22847932</pub-id><pub-id pub-id-type="pmcid">3463124</pub-id></element-citation></ref>
<ref id="b16-mmr-13-05-3779"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Ronghe</surname><given-names>AM</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Bhat</surname><given-names>NK</given-names></name><name><surname>Bhat</surname><given-names>HK</given-names></name></person-group><article-title>MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis</article-title><source>Carcinogenesis</source><volume>34</volume><fpage>1165</fpage><lpage>1172</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/carcin/bgt026</pub-id><pub-id pub-id-type="pmid">23492819</pub-id><pub-id pub-id-type="pmcid">3643421</pub-id></element-citation></ref>
<ref id="b17-mmr-13-05-3779"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chand</surname><given-names>Y</given-names></name><name><surname>Alam</surname><given-names>MA</given-names></name></person-group><article-title>Network biology approach for identifying key regulatory genes by expression based study of breast cancer</article-title><source>Bioinformation</source><volume>8</volume><fpage>1132</fpage><lpage>1138</lpage><year>2012</year><pub-id pub-id-type="doi">10.6026/97320630081132</pub-id><pub-id pub-id-type="pmcid">3530881</pub-id></element-citation></ref>
<ref id="b18-mmr-13-05-3779"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title><source>J R Stat Soc Series B Stat Methodol</source><fpage>289</fpage><lpage>300</lpage><year>1995</year></element-citation></ref>
<ref id="b19-mmr-13-05-3779"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name></person-group><article-title>Discovering the false discovery rate</article-title><source>J R Stat Soc Series B Stat Methodol</source><volume>72</volume><fpage>405</fpage><lpage>416</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1467-9868.2010.00746.x</pub-id></element-citation></ref>
<ref id="b20-mmr-13-05-3779"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name></person-group><article-title>Finding consistent disease subnetworks using PFSNet</article-title><source>Bioinformatics</source><volume>30</volume><fpage>189</fpage><lpage>196</lpage><year>2014</year><pub-id pub-id-type="doi">10.1093/bioinformatics/btt625</pub-id></element-citation></ref>
<ref id="b21-mmr-13-05-3779"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soh</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name></person-group><article-title>Consistency, comprehensiveness, and compatibility of pathway databases</article-title><source>BMC Bioinformatics</source><volume>11</volume><fpage>449</fpage><year>2010</year><pub-id pub-id-type="doi">10.1186/1471-2105-11-449</pub-id><pub-id pub-id-type="pmid">20819233</pub-id><pub-id pub-id-type="pmcid">2944280</pub-id></element-citation></ref>
<ref id="b22-mmr-13-05-3779"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelder</surname><given-names>T</given-names></name><name><surname>van Iersel</surname><given-names>MP</given-names></name><name><surname>Hanspers</surname><given-names>K</given-names></name><name><surname>Kutmon</surname><given-names>M</given-names></name><name><surname>Conklin</surname><given-names>BR</given-names></name><name><surname>Evelo</surname><given-names>CT</given-names></name><name><surname>Pico</surname><given-names>AR</given-names></name></person-group><article-title>WikiPathways: Building research communities on biological pathways</article-title><source>Nucleic Acids Res</source><volume>40</volume><issue>Database Issue</issue><fpage>D1301</fpage><lpage>D1307</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/nar/gkr1074</pub-id><pub-id pub-id-type="pmcid">3245032</pub-id></element-citation></ref>
<ref id="b23-mmr-13-05-3779"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Furumichi</surname><given-names>M</given-names></name><name><surname>Tanabe</surname><given-names>M</given-names></name></person-group><article-title>KEGG for integration and interpretation of large-scale molecular data sets</article-title><source>Nucleic Acids Res</source><volume>40</volume><issue>Database Issue</issue><fpage>D109</fpage><lpage>D114</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/nar/gkr988</pub-id><pub-id pub-id-type="pmcid">3245020</pub-id></element-citation></ref>
<ref id="b24-mmr-13-05-3779"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000E4;mer</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Pollard</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Tugendreich</surname><given-names>S</given-names></name></person-group><article-title>Causal analysis approaches in ingenuity pathway analysis</article-title><source>Bioinformatics</source><volume>30</volume><fpage>523</fpage><lpage>530</lpage><year>2014</year><pub-id pub-id-type="doi">10.1093/bioinformatics/btt703</pub-id><pub-id pub-id-type="pmcid">3928520</pub-id></element-citation></ref>
<ref id="b25-mmr-13-05-3779"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>Screening and bioinformatics analysis of differentially expressed genes in hyperplastic scar</article-title><source>Nan Fang Yi Ke Da Xue Xue Bao</source><volume>34</volume><fpage>939</fpage><lpage>944</lpage><year>2014</year><comment>In Chinese</comment><pub-id pub-id-type="pmid">25057060</pub-id></element-citation></ref>
<ref id="b26-mmr-13-05-3779"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Frankild</surname><given-names>S</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Simonovic</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Minguez</surname><given-names>P</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>von Mering</surname><given-names>C</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name></person-group><article-title>STRING v9.1: Protein-protein interaction networks, with increased coverage and integration</article-title><source>Nucleic Acids Res</source><volume>41</volume><issue>Database Issue</issue><fpage>D808</fpage><lpage>D815</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/nar/gks1094</pub-id><pub-id pub-id-type="pmcid">3531103</pub-id></element-citation></ref>
<ref id="b27-mmr-13-05-3779"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Markiel</surname><given-names>A</given-names></name><name><surname>Ozier</surname><given-names>O</given-names></name><name><surname>Baliga</surname><given-names>NS</given-names></name><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Ramage</surname><given-names>D</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Schwikowski</surname><given-names>B</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name></person-group><article-title>Cytoscape: A software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res</source><volume>13</volume><fpage>2498</fpage><lpage>2504</lpage><year>2003</year><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id><pub-id pub-id-type="pmcid">403769</pub-id></element-citation></ref>
<ref id="b28-mmr-13-05-3779"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldmann</surname><given-names>G</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Bisht</surname><given-names>S</given-names></name><name><surname>Karikari</surname><given-names>C</given-names></name><name><surname>Garrido-Laguna</surname><given-names>I</given-names></name><name><surname>Rasheed</surname><given-names>Z</given-names></name><name><surname>Ottenhof</surname><given-names>NA</given-names></name><name><surname>Dadon</surname><given-names>T</given-names></name><name><surname>Alvarez</surname><given-names>H</given-names></name><name><surname>Fendrich</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models</article-title><source>Cancer Biol Ther</source><volume>12</volume><fpage>598</fpage><lpage>609</lpage><year>2011</year><pub-id pub-id-type="doi">10.4161/cbt.12.7.16475</pub-id><pub-id pub-id-type="pmid">21768779</pub-id><pub-id pub-id-type="pmcid">3218385</pub-id></element-citation></ref>
<ref id="b29-mmr-13-05-3779"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hempen</surname><given-names>PM</given-names></name><name><surname>Kurpad</surname><given-names>H</given-names></name><name><surname>Calhoun</surname><given-names>ES</given-names></name><name><surname>Abraham</surname><given-names>S</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><article-title>A double missense variation of the BUB1 gene and a defective mitotic spindle checkpoint in the pancreatic cancer cell line Hs766T</article-title><source>Hum Mutat</source><volume>21</volume><fpage>445</fpage><year>2003</year><pub-id pub-id-type="doi">10.1002/humu.9120</pub-id><pub-id pub-id-type="pmid">12655561</pub-id></element-citation></ref>
<ref id="b30-mmr-13-05-3779"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zou</surname><given-names>M</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Development of serum parameters panels for the early detection of pancreatic cancer</article-title><source>Int J Cancer</source><volume>134</volume><fpage>2646</fpage><lpage>2655</lpage><year>2014</year><pub-id pub-id-type="doi">10.1002/ijc.28584</pub-id><pub-id pub-id-type="pmid">24615168</pub-id></element-citation></ref>
<ref id="b31-mmr-13-05-3779"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renouf</surname><given-names>D</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name></person-group><article-title>Evolution of systemic therapy for advanced pancreatic cancer</article-title><source>Expert Rev Anticancer Ther</source><volume>10</volume><fpage>529</fpage><lpage>540</lpage><year>2010</year><pub-id pub-id-type="doi">10.1586/era.10.21</pub-id><pub-id pub-id-type="pmid">20397918</pub-id></element-citation></ref>
<ref id="b32-mmr-13-05-3779"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusakai</surname><given-names>G</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Kaminishi</surname><given-names>M</given-names></name><name><surname>Esumi</surname><given-names>H</given-names></name></person-group><article-title>Strong association of ARK5 with tumor invasion and metastasis</article-title><source>J Exp Clin Cancer Res</source><volume>23</volume><fpage>263</fpage><lpage>268</lpage><year>2004</year><pub-id pub-id-type="pmid">15354411</pub-id></element-citation></ref>
<ref id="b33-mmr-13-05-3779"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokkinakis</surname><given-names>DM</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Neuner</surname><given-names>RD</given-names></name></person-group><article-title>Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): Implications to the therapy of pancreatic adenocarcinoma</article-title><source>Mol Cancer Ther</source><volume>4</volume><fpage>1338</fpage><lpage>1348</lpage><year>2005</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0141</pub-id><pub-id pub-id-type="pmid">16170025</pub-id></element-citation></ref>
<ref id="b34-mmr-13-05-3779"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michl</surname><given-names>P</given-names></name><name><surname>Buchholz</surname><given-names>M</given-names></name><name><surname>Rolke</surname><given-names>M</given-names></name><name><surname>Kunsch</surname><given-names>S</given-names></name><name><surname>L&#x000F6;hr</surname><given-names>M</given-names></name><name><surname>McClane</surname><given-names>B</given-names></name><name><surname>Tsukita</surname><given-names>S</given-names></name><name><surname>Leder</surname><given-names>G</given-names></name><name><surname>Adler</surname><given-names>G</given-names></name><name><surname>Gress</surname><given-names>TM</given-names></name></person-group><article-title>Claudin-4: A new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin</article-title><source>Gastroenterology</source><volume>121</volume><fpage>678</fpage><lpage>684</lpage><year>2001</year><pub-id pub-id-type="doi">10.1053/gast.2001.27124</pub-id><pub-id pub-id-type="pmid">11522752</pub-id></element-citation></ref>
<ref id="b35-mmr-13-05-3779"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dun</surname><given-names>B</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>She</surname><given-names>JX</given-names></name></person-group><article-title>Transcriptomic changes induced by mycophenolic acid in gastric cancer cells</article-title><source>Am J Transl Res</source><volume>6</volume><fpage>28</fpage><lpage>42</lpage><year>2013</year><pub-id pub-id-type="pmid">24349619</pub-id><pub-id pub-id-type="pmcid">3853422</pub-id></element-citation></ref>
<ref id="b36-mmr-13-05-3779"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>D</given-names></name><name><surname>Pomerening</surname><given-names>JR</given-names></name><name><surname>Myers</surname><given-names>JW</given-names></name><name><surname>Gustavsson</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>JT</given-names></name><name><surname>Hahn</surname><given-names>AT</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name><name><surname>Ferrell</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>Cyclin A2 regulates nuclear-envelope breakdown and the nuclear accumulation of cyclin B1</article-title><source>Curr Biol</source><volume>17</volume><fpage>85</fpage><lpage>91</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.cub.2006.11.066</pub-id><pub-id pub-id-type="pmid">17208191</pub-id><pub-id pub-id-type="pmcid">1830184</pub-id></element-citation></ref>
<ref id="b37-mmr-13-05-3779"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>SE</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>YI</given-names></name><name><surname>Kang</surname><given-names>MY</given-names></name><name><surname>Jung</surname><given-names>EH</given-names></name><name><surname>Ko</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Shim</surname><given-names>YM</given-names></name><name><surname>Park</surname><given-names>J</given-names></name></person-group><article-title>A functional single nucleotide polymorphism at the promoter region of cyclin A2 is associated with increased risk of colon, liver and lung cancers</article-title><source>Cancer</source><volume>117</volume><fpage>4080</fpage><lpage>4091</lpage><year>2011</year><pub-id pub-id-type="doi">10.1002/cncr.25930</pub-id><pub-id pub-id-type="pmid">21858804</pub-id></element-citation></ref>
<ref id="b38-mmr-13-05-3779"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Ao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name></person-group><article-title>CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance</article-title><source>PLoS One</source><volume>9</volume><fpage>e91771</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0091771</pub-id><pub-id pub-id-type="pmid">24622579</pub-id><pub-id pub-id-type="pmcid">3951414</pub-id></element-citation></ref>
<ref id="b39-mmr-13-05-3779"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokkinakis</surname><given-names>DM</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Neuner</surname><given-names>RD</given-names></name></person-group><article-title>Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): Implications to the therapy of pancreatic adenocarcinoma</article-title><source>Mol Cancer Ther</source><volume>4</volume><fpage>1338</fpage><lpage>1348</lpage><year>2005</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0141</pub-id><pub-id pub-id-type="pmid">16170025</pub-id></element-citation></ref>
<ref id="b40-mmr-13-05-3779"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roderick</surname><given-names>HL</given-names></name><name><surname>Cook</surname><given-names>SJ</given-names></name></person-group><article-title>Ca<sup>2+</sup> signalling checkpoints in cancer: Remodelling Ca<sup>2+</sup> for cancer cell proliferation and survival</article-title><source>Nat Rev Cancer</source><volume>8</volume><fpage>361</fpage><lpage>375</lpage><year>2008</year><pub-id pub-id-type="doi">10.1038/nrc2374</pub-id><pub-id pub-id-type="pmid">18432251</pub-id></element-citation></ref>
<ref id="b41-mmr-13-05-3779"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Arribas</surname><given-names>J</given-names></name></person-group><article-title>Treating cancer's kinase 'addiction'</article-title><source>Nat Med</source><volume>10</volume><fpage>786</fpage><lpage>787</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/nm0804-786</pub-id><pub-id pub-id-type="pmid">15286778</pub-id></element-citation></ref>
<ref id="b42-mmr-13-05-3779"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettencourt-Dias</surname><given-names>M</given-names></name><name><surname>Giet</surname><given-names>R</given-names></name><name><surname>Sinka</surname><given-names>R</given-names></name><name><surname>Mazumdar</surname><given-names>A</given-names></name><name><surname>Lock</surname><given-names>WG</given-names></name><name><surname>Balloux</surname><given-names>F</given-names></name><name><surname>Zafiropoulos</surname><given-names>PJ</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Winter</surname><given-names>S</given-names></name><name><surname>Carthew</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Genome-wide survey of protein kinases required for cell cycle progression</article-title><source>Nature</source><volume>432</volume><fpage>980</fpage><lpage>987</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/nature03160</pub-id><pub-id pub-id-type="pmid">15616552</pub-id></element-citation></ref>
<ref id="b43-mmr-13-05-3779"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaudet</surname><given-names>S</given-names></name><name><surname>Branton</surname><given-names>D</given-names></name><name><surname>Lue</surname><given-names>RA</given-names></name></person-group><article-title>Characterization of PDZ-binding kinase, a mitotic kinase</article-title><source>Proc Natl Acad Sci USA</source><volume>97</volume><fpage>5167</fpage><lpage>5172</lpage><year>2000</year><pub-id pub-id-type="doi">10.1073/pnas.090102397</pub-id><pub-id pub-id-type="pmid">10779557</pub-id><pub-id pub-id-type="pmcid">25800</pub-id></element-citation></ref>
<ref id="b44-mmr-13-05-3779"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Lin</surname><given-names>ML</given-names></name><name><surname>Nishidate</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Katagiri</surname><given-names>T</given-names></name></person-group><article-title>PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer</article-title><source>Cancer Res</source><volume>66</volume><fpage>9186</fpage><lpage>9195</lpage><year>2006</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1601</pub-id><pub-id pub-id-type="pmid">16982762</pub-id></element-citation></ref>
<ref id="b45-mmr-13-05-3779"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandi</surname><given-names>AK</given-names></name><name><surname>Rapoport</surname><given-names>AP</given-names></name></person-group><article-title>Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATF</article-title><source>Leuk Res</source><volume>30</volume><fpage>437</fpage><lpage>447</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.leukres.2005.08.011</pub-id></element-citation></ref>
<ref id="b46-mmr-13-05-3779"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayll&#x000F3;n</surname><given-names>V</given-names></name><name><surname>O'connor</surname><given-names>R</given-names></name></person-group><article-title>PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response</article-title><source>Oncogene</source><volume>26</volume><fpage>3451</fpage><lpage>3461</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/sj.onc.1210142</pub-id></element-citation></ref>
<ref id="b47-mmr-13-05-3779"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandi</surname><given-names>AK</given-names></name><name><surname>Ford</surname><given-names>T</given-names></name><name><surname>Fleksher</surname><given-names>D</given-names></name><name><surname>Neuman</surname><given-names>B</given-names></name><name><surname>Rapoport</surname><given-names>AP</given-names></name></person-group><article-title>Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53</article-title><source>Biochem Biophys Res Commun</source><volume>358</volume><fpage>181</fpage><lpage>188</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.04.125</pub-id><pub-id pub-id-type="pmid">17482142</pub-id></element-citation></ref>
<ref id="b48-mmr-13-05-3779"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirohashi</surname><given-names>S</given-names></name><name><surname>Kanai</surname><given-names>Y</given-names></name></person-group><article-title>Cell adhesion system and human cancer morphogenesis</article-title><source>Cancer Sci</source><volume>94</volume><fpage>575</fpage><lpage>581</lpage><year>2003</year><pub-id pub-id-type="doi">10.1111/j.1349-7006.2003.tb01485.x</pub-id><pub-id pub-id-type="pmid">12841864</pub-id></element-citation></ref>
<ref id="b49-mmr-13-05-3779"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saiki</surname><given-names>I</given-names></name></person-group><article-title>Cell adhesion molecules and cancer metastasis</article-title><source>Jpn J Pharmacol</source><volume>75</volume><fpage>215</fpage><lpage>242</lpage><year>1997</year><pub-id pub-id-type="doi">10.1254/jjp.75.215</pub-id></element-citation></ref>
<ref id="b50-mmr-13-05-3779"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Mu&#x000F1;oz</surname><given-names>AR</given-names></name><name><surname>Chan</surname><given-names>D</given-names></name><name><surname>Ghosh</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>AP</given-names></name></person-group><article-title>STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth</article-title><source>Oncotarget</source><volume>5</volume><fpage>2529</fpage><lpage>2541</lpage><year>2014</year><pub-id pub-id-type="doi">10.18632/oncotarget.1810</pub-id><pub-id pub-id-type="pmid">24796733</pub-id><pub-id pub-id-type="pmcid">4058024</pub-id></element-citation></ref>
<ref id="b51-mmr-13-05-3779"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heukamp</surname><given-names>I</given-names></name><name><surname>Kilian</surname><given-names>M</given-names></name><name><surname>Gregor</surname><given-names>JI</given-names></name><name><surname>Kiewert</surname><given-names>C</given-names></name><name><surname>Schimke</surname><given-names>I</given-names></name><name><surname>Kristiansen</surname><given-names>G</given-names></name><name><surname>Walz</surname><given-names>MK</given-names></name><name><surname>Jacobi</surname><given-names>CA</given-names></name><name><surname>Wenger</surname><given-names>FA</given-names></name></person-group><article-title>Impact of polyunsaturated fatty acids on hepato-pancreatic prostaglandin and leukotriene concentration in ductal pancreatic cancer-is there a correlation to tumour growth and liver metastasis?</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><volume>74</volume><fpage>223</fpage><lpage>233</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.plefa.2006.01.005</pub-id><pub-id pub-id-type="pmid">16556492</pub-id></element-citation></ref>
<ref id="b52-mmr-13-05-3779"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aravindan</surname><given-names>S</given-names></name><name><surname>Delma</surname><given-names>CR</given-names></name><name><surname>Thirugnanasambandan</surname><given-names>SS</given-names></name><name><surname>Herman</surname><given-names>TS</given-names></name><name><surname>Aravindan</surname><given-names>N</given-names></name></person-group><article-title>Anti-pancreatic cancer deliverables from sea: First-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae</article-title><source>PLoS One</source><volume>8</volume><fpage>e61977</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0061977</pub-id><pub-id pub-id-type="pmid">23613993</pub-id><pub-id pub-id-type="pmcid">3628576</pub-id></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-mmr-13-05-3779" position="float">
<label>Figure 1</label>
<caption>
<p>Five significant subnetworks of the N-group, associated with (A) glutathione metabolism (B) leucine and isoleucine metabolism (C) pancreatic cancer (D) calcium signaling pathway and (E) the mitogen-activated protein kinase pathway. Red nodes indicate upregulated genes and blue nodes downregulated genes.</p></caption>
<graphic xlink:href="MMR-13-05-3779-g00.jpg"/></fig>
<fig id="f2-mmr-13-05-3779" position="float">
<label>Figure 2</label>
<caption>
<p>Five significant subnetworks of genes from the T-group, associated with (A) galactose metabolism (B) alanine, (C) aspartic acid and glutamic acid metabolism, (D) intercellular junction and (E) contraction of vascular smooth muscle. Red nodes represent the upregulated genes and the blue nodes represent downregulated genes.</p></caption>
<graphic xlink:href="MMR-13-05-3779-g01.jpg"/></fig>
<fig id="f3-mmr-13-05-3779" position="float">
<label>Figure 3</label>
<caption>
<p>Pathway enrichment for differentially expressed genes. (A) Upregulated genes and (B) downregulated genes.</p></caption>
<graphic xlink:href="MMR-13-05-3779-g02.jpg"/></fig>
<fig id="f4-mmr-13-05-3779" position="float">
<label>Figure 4</label>
<caption>
<p>Significant module of (A) upregulated genes and (B) downregulated genes. Red nodes represent the upregulated DEGs. While blue nodes represent downregulated genes.</p></caption>
<graphic xlink:href="MMR-13-05-3779-g03.jpg"/></fig>
<table-wrap id="tI-mmr-13-05-3779" position="float">
<label>Table I</label>
<caption>
<p>Top gene ontology functional enrichment of up- and downregulated genes.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="3" valign="top" align="left">A, Upregulated
<hr/></th></tr>
<tr>
<th valign="top" align="left">Term</th>
<th valign="top" align="center">Gene count</th>
<th valign="top" align="center">P-value</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">GO:0007155~cell adhesion</td>
<td valign="top" align="center">73</td>
<td valign="top" align="center">&lt;0.001</td></tr>
<tr>
<td valign="top" align="left">GO:0022610~biological adhesion</td>
<td valign="top" align="center">73</td>
<td valign="top" align="center">&lt;0.001</td></tr>
<tr>
<td valign="top" align="left">GO:0006955~immune response</td>
<td valign="top" align="center">66</td>
<td valign="top" align="center">&lt;0.001</td></tr>
<tr>
<td valign="top" align="left">GO:0006952~defense response</td>
<td valign="top" align="center">59</td>
<td valign="top" align="center">0.000001</td></tr>
<tr>
<td valign="top" align="left">GO:0042127~regulation of cell proliferation</td>
<td valign="top" align="center">58</td>
<td valign="top" align="center">0.001423</td></tr>
<tr>
<td valign="top" align="left">GO:0007049~cell cycle</td>
<td valign="top" align="center">57</td>
<td valign="top" align="center">0.001696</td></tr>
<tr>
<td valign="top" align="left">GO:0009611~response to wounding</td>
<td valign="top" align="center">52</td>
<td valign="top" align="center">0.000002</td></tr>
<tr>
<td valign="top" align="left">GO:0010033~response to organic substance</td>
<td valign="top" align="center">51</td>
<td valign="top" align="center">0.006513</td></tr>
<tr>
<td valign="top" align="left">GO:0055114~oxidation reduction</td>
<td valign="top" align="center">47</td>
<td valign="top" align="center">0.004401</td></tr>
<tr>
<td valign="top" align="left">GO:0022402~cell cycle process</td>
<td valign="top" align="center">46</td>
<td valign="top" align="center">0.000678</td></tr>
<tr>
<td valign="top" align="left">GO:0008219~cell death</td>
<td valign="top" align="center">46</td>
<td valign="top" align="center">0.046477</td></tr>
<tr>
<td valign="top" align="left">GO:0016265~death</td>
<td valign="top" align="center">46</td>
<td valign="top" align="center">0.047681</td></tr>
<tr>
<td valign="top" align="left">GO:0008283~cell proliferation</td>
<td valign="top" align="center">43</td>
<td valign="top" align="center">0.000016</td></tr>
<tr>
<td valign="top" align="left">GO:0022403~cell cycle phase</td>
<td valign="top" align="center">41</td>
<td valign="top" align="center">0.000024</td></tr></tbody></table>
<table frame="below" rules="groups">
<thead>
<tr>
<th colspan="3" valign="top" align="left">B, Downregulated
<hr/></th></tr>
<tr>
<th valign="top" align="left">Term</th>
<th valign="top" align="center">Gene count</th>
<th valign="top" align="center">P-value</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">GO:0006508~proteolysis</td>
<td valign="top" align="center">33</td>
<td valign="top" align="center">0.000243</td></tr>
<tr>
<td valign="top" align="left">GO:0010033~response to organic substance</td>
<td valign="top" align="center">24</td>
<td valign="top" align="center">0.001006</td></tr>
<tr>
<td valign="top" align="left">GO:0006811~ion transport</td>
<td valign="top" align="center">22</td>
<td valign="top" align="center">0.009722</td></tr>
<tr>
<td valign="top" align="left">GO:0042592~homeostatic process</td>
<td valign="top" align="center">21</td>
<td valign="top" align="center">0.015010</td></tr>
<tr>
<td valign="top" align="left">GO:0009611~response to wounding</td>
<td valign="top" align="center">20</td>
<td valign="top" align="center">0.000721</td></tr>
<tr>
<td valign="top" align="left">GO:0048878~chemical homeostasis</td>
<td valign="top" align="center">18</td>
<td valign="top" align="center">0.003062</td></tr>
<tr>
<td valign="top" align="left">GO:0009719~response to endogenous stimulus</td>
<td valign="top" align="center">17</td>
<td valign="top" align="center">0.000678</td></tr>
<tr>
<td valign="top" align="left">GO:0019725~cellular homeostasis</td>
<td valign="top" align="center">17</td>
<td valign="top" align="center">0.002910</td></tr>
<tr>
<td valign="top" align="left">GO:0009725~response to hormone stimulus</td>
<td valign="top" align="center">16</td>
<td valign="top" align="center">0.000718</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-mmr-13-05-3779">
<p>Term, Gene Ontology pathway name; gene counts, number of differentially expressed genes enriched in the Gene Ontology function.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tII-mmr-13-05-3779" position="float">
<label>Table II</label>
<caption>
<p>Top Gene Ontology annotation of up- and downregulated genes in the significant module with the lowest P-value of the protein-protein interaction network.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="3" valign="top" align="left">A, Upregulated
<hr/></th></tr>
<tr>
<th valign="top" align="left">Term</th>
<th valign="top" align="center">Gene count</th>
<th valign="top" align="center">P-value</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">GO:0007049~cell cycle</td>
<td valign="top" align="center">44</td>
<td valign="top" align="center">&lt;0.001</td></tr>
<tr>
<td valign="top" align="left">GO:0022402~cell cycle process</td>
<td valign="top" align="center">38</td>
<td valign="top" align="center">&lt;0.001</td></tr>
<tr>
<td valign="top" align="left">GO:0022403~cell cycle phase</td>
<td valign="top" align="center">37</td>
<td valign="top" align="center">&lt;0.001</td></tr>
<tr>
<td valign="top" align="left">GO:0000279~M phase</td>
<td valign="top" align="center">36</td>
<td valign="top" align="center">&lt;0.001</td></tr>
<tr>
<td valign="top" align="left">GO:0000278~mitotic cell cycle</td>
<td valign="top" align="center">32</td>
<td valign="top" align="center">&lt;0.001</td></tr>
<tr>
<td valign="top" align="left">GO:0051301~cell division</td>
<td valign="top" align="center">29</td>
<td valign="top" align="center">&lt;0.001</td></tr></tbody></table>
<table frame="below" rules="groups">
<thead>
<tr>
<th colspan="3" valign="top" align="left">B, Downregulated
<hr/></th></tr>
<tr>
<th valign="top" align="left">Term</th>
<th valign="top" align="center">Gene count</th>
<th valign="top" align="center">P-value</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">GO:0006508~proteolysis</td>
<td valign="top" align="center">15</td>
<td valign="top" align="center">0.000234</td></tr>
<tr>
<td valign="top" align="left">GO:0009611~response to wounding</td>
<td valign="top" align="center">11</td>
<td valign="top" align="center">0.000134</td></tr>
<tr>
<td valign="top" align="left">GO:0010033~response to organic substance</td>
<td valign="top" align="center">11</td>
<td valign="top" align="center">0.001507</td></tr>
<tr>
<td valign="top" align="left">GO:0009725~response to hormone stimulus</td>
<td valign="top" align="center">9</td>
<td valign="top" align="center">0.000256</td></tr>
<tr>
<td valign="top" align="left">GO:0009719~response to endogenous stimulus</td>
<td valign="top" align="center">9</td>
<td valign="top" align="center">0.000495</td></tr>
<tr>
<td valign="top" align="left">GO:0042127~regulation of cell proliferation</td>
<td valign="top" align="center">9</td>
<td valign="top" align="center">0.026531</td></tr></tbody></table></table-wrap></floats-group></article>
